We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.
Hilary Campbell, PharmD, JD
Advertisement
Articles by Hilary Campbell, PharmD, JD
Advertisement
Latest Updated Articles
- Value-Based Arrangements May Be More Prevalent Than Assumed
Published: February 13th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
4
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
5
